Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.35 |
| ▸ | CPA1 | P15085 | 2/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.33 |
| ▸ | CPB1 | P15086 | 2/20 | 0.33 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10130923 | 0.84 | MAPT (0.44) | GRIA1EGLN1HCAR2PANK3S1PR1 | |
| SCHEMBL13623262 | 0.83 | NOS3 (0.36) | GRIA1EGLN1ALDH1A1TDP1 | |
| SCHEMBL20390770 | 0.80 | EGLN1 (0.32) | GRIA1EGLN1 | |
| SCHEMBL10130925 | 0.79 | IDH1 (0.38) | GRIA1HCAR2 | |
| SCHEMBL4353130 | 0.78 | IDO1 (0.38) | EGLN1 | |
| SCHEMBL13623581 | 0.77 | GABRP (0.36) | GRIA1EGLN1 | |
| SCHEMBL13615879 | 0.77 | EGLN1 (0.38) | GRIA1EGLN1HCAR2ALDH1A1 | |
| SCHEMBL10130939 | 0.77 | CYP11B1 (0.40) | EGLN1ALDH1A1TDP1 | |
| SCHEMBL10130936 | 0.77 | GRIA1 (0.35) | GRIA1HCAR2ALDH1A1TDP1 | |
| SCHEMBL14207819 | 0.77 | EGLN1 (0.41) | CPB2CPA1EGLN1HCAR2CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231298-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8383785-B2 | Anti-bacterial activity of 9-hydroxy derivatives of 6,11-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383785-B2 | Anti-bacterial activity of 9-hydroxy derivatives of 6,11-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20090281050-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-11-12 | — | — | US | disclosed |
| US-20090281050-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231298-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | CYP8B1, SI, CYP51A1 | CPB2 885/4885GRIA1 4825/4885CPA1 2054/4885 |
| US-20090281050-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | CYP8B1, SI, CYP51A1 | CPB2 885/4885GRIA1 4825/4885CPA1 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.